Paola Sabrina Buonuomo1, Andrea Bartuli1, Claudio Rabacchi2, Stefano Bertolini3, Sebastiano Calandra4. 1. Rare Diseases and Medical Genetics, Bambino Gesù Children Hospital, Rome, Italy. 2. Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy. 3. Department of Internal Medicine, University of Genova, Genova, Italy. 4. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. Electronic address: sebcal@unimore.it.
Abstract
BACKGROUND: Familial chylomicronemia is a genetic defect of the intravascular lipolysis of triglyceride (TG)-rich lipoproteins. Intravascular lipolysis involves the TG-hydrolase lipoprotein lipase (LPL) as well as other factors such as apolipoprotein CII and apolipoprotein AV (activators of LPL), GPIHBP1 (the molecular platform required for LPL activity on endothelial surface), and LMF1 (a factor required for intracellular formation of active LPL). METHODS: We sequenced the familial chylomicronemia candidate genes in a neonate with chylomicronemia. RESULTS: A 3-day-old newborn was found to have chylomicronemia (plasma TG 18.8 mmol/L, 1.667 mg/dL). The discontinuation of breastfeeding for 24 hours reduced plasma TG to 2.3 mmol/L (201 mg/dL), whereas its resumption induced a sharp TG increase (7.9 mmol/L, 690 mg/dL). The child was switched to a low-fat diet, which was effective in maintaining TG level below 3.5 mmol/L (294 mg/dL) during the first months of life. The child was found to be a compound heterozygous for 2 novel mutations in GPIHBP1 gene. The first mutation was a 9-bp deletion and 4-bp insertion in exon 2, causing a frameshift that abolished the canonical termination codon TGA. The predicted translation product of the mutant messenger RNA is a peptide that contains 51 amino acids of the N-terminal end of the wild-type protein followed by 252 novel amino acids. The second mutation was a nucleotide change (c.319T>C), causing an amino acid substitution p.(Ser107Pro) predicted in silico to be damaging. CONCLUSIONS: GPIHBP1 mutations should be considered in neonates with chylomicronemia negative for mutations in LPL gene.
BACKGROUND:Familial chylomicronemia is a genetic defect of the intravascular lipolysis of triglyceride (TG)-rich lipoproteins. Intravascular lipolysis involves the TG-hydrolase lipoprotein lipase (LPL) as well as other factors such as apolipoprotein CII and apolipoprotein AV (activators of LPL), GPIHBP1 (the molecular platform required for LPL activity on endothelial surface), and LMF1 (a factor required for intracellular formation of active LPL). METHODS: We sequenced the familial chylomicronemia candidate genes in a neonate with chylomicronemia. RESULTS: A 3-day-old newborn was found to have chylomicronemia (plasma TG 18.8 mmol/L, 1.667 mg/dL). The discontinuation of breastfeeding for 24 hours reduced plasma TG to 2.3 mmol/L (201 mg/dL), whereas its resumption induced a sharp TG increase (7.9 mmol/L, 690 mg/dL). The child was switched to a low-fat diet, which was effective in maintaining TG level below 3.5 mmol/L (294 mg/dL) during the first months of life. The child was found to be a compound heterozygous for 2 novel mutations in GPIHBP1 gene. The first mutation was a 9-bp deletion and 4-bp insertion in exon 2, causing a frameshift that abolished the canonical termination codon TGA. The predicted translation product of the mutant messenger RNA is a peptide that contains 51 amino acids of the N-terminal end of the wild-type protein followed by 252 novel amino acids. The second mutation was a nucleotide change (c.319T>C), causing an amino acid substitution p.(Ser107Pro) predicted in silico to be damaging. CONCLUSIONS:GPIHBP1 mutations should be considered in neonates with chylomicronemia negative for mutations in LPL gene.
Authors: Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux Journal: J Clin Lipidol Date: 2017-06-13 Impact factor: 4.766
Authors: Simon Mysling; Kristian Kølby Kristensen; Mikael Larsson; Anne P Beigneux; Henrik Gårdsvoll; Loren G Fong; André Bensadouen; Thomas Jd Jørgensen; Stephen G Young; Michael Ploug Journal: Elife Date: 2016-01-03 Impact factor: 8.140
Authors: Nehal M El-Koofy; Yasmeen A Abdo; Dina El-Fayoumi; Amanne F Esmael; Mohamed A Elmonem; Zahraa Ezzeldin Journal: Lipids Health Dis Date: 2021-04-20 Impact factor: 3.876
Authors: Kristian Kølby Kristensen; Katrine Zinck Leth-Espensen; Anni Kumari; Anne Louise Grønnemose; Anne-Marie Lund-Winther; Stephen G Young; Michael Ploug Journal: Front Cell Dev Biol Date: 2021-07-15